American Thoracic Society International Conference

Smokers who quit had lower disease risk than the group identified as stable, low-rate smokers.

Sanofi and Regeneron reported promising results from a pair of pivotal phase 3 trials for the investigative add-on therapy.

From food deserts to hazardous jobs that inhibit exposure and limit the means to prevent it, people of low SES are at greatest environmental health risk.

Researchers intend to follow observed infants into early childhood to gauge the vitamin's influence on pediatric asthma rates.

Children given immunocap radioallergosorbent tests when hospitalized for asthma avoided re-hopsitalization twice as long as children not given the test.

A type of flavonoid found in dark-pigmented fruits like red grapes and blueberries may slow the lung function decline that occurs with aging.

The inhaled corticosteroid from GSK is indicated for pediatric asthma patients aged 5-11 years old.

Older people adhering to the antioxidant-rich diet were less likely die from cardiovascular conditions when exposed to greater ambient air pollution.

The monoclonal antibody reported quick and consistent exacerbation rate reduction in patients with severe eosinophilic asthma.

The once-daily, triple-drug inhaler therapy reported improvements in exacerbation rate and risk to first event.

Over 16 months, a greater rate of patients reported returning visits, proper inhaler use understadning, and overall satisfcation.

Reducing use of opiates near the end of hospital stay, especially 24 hours prior to discharge, may reduce outpatient prescription of opioids.

Infants whose mothers were exposed to carbon monoxide in the second and third trimester were at highest risk for reduced lung function when they were tested at 1 month of age.

The therapy showed reduction in nighttime resting heart rate comparable to that of beta blockers.

The hazard ratios for ozone measured at bone as a single pollutant showed statistically significant higher risks for development of asthma, allergic rhinitis and eczema.

Simvastatin may reduce inflammation, fibrosis, bronchial constriction, mucus

Doctors need to conduct clinical trials and define the disease.

Neomi Shah, MD, MPH, studied patients with sleep apnea to uncover its effect on arterial inflammation.

Valerie Page, MB, BCh, FRCA, recounts a study of simvastatin on delirium patients.

Michael Wechsler, MD, MMSc, recounts the phase III trial of Mepolizumab on patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Drug meets all primary and secondary end points in phase III study.

Revefenacin improved trough FEV1 versus placebo in two phase 3 trials for COPD.

Benralizumab led to a 75% reduction in the use of oral corticosteroids for severe asthma.

PBI-4050 slowed or stopped declines in lung function in patients with IPF.

Asthma patients woke up less often and improved faster with FF/VI

Ambulatory oxygen improved symptoms, performance, and recovery time in fibrotic ILDs.

MK-7264 reduced cough frequency by 37% for patients with chronic cough.

ICOS and CD28 expression levels on CD4 T cells effectively predicted survival for patients with idiopathic pulmonary fibrosis.

Older patients and sick patients are at increased risk.